The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

PET Radiopharmaceuticals for Tumor Imaging

종양 영상을 위한 PET 방사성의약품

  • Choe, Yearn-Seong (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 최연성 (성균관대학교 의과대학 삼성서울병원 핵의학과)
  • Published : 2002.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Early and accurate diagnosis of tumors using positron omission tomography (PET) has been the focus of considerable interest due to its high metastasis and mortality rates at late detection. PET radiopharmaceuticals-which exhibit a high tumor-to-background uptake ratio, and appropriate metabolic characteristics, and pharmacokinetics-are attractive tools for tumor imaging. Tumor imaging by these radiopharmaceuticals are based on metabolic and receptor imaging. The former is based on accelerated metabolism in tumor tissue compared to normal tissue and the rate roughly corresponding to the rate of growth of tumors. Radiopharmaceuticals for this purpose include radiolabeled sugars, amino acids, and nucleosides which detect increased glucose utilization, protein synthesis, and DNA synthesis, respectively. Tumor receptor imaging is based on the proliferation of tumor cells regulated by many hormones and growth factors, which bind to the corresponding receptors and exhibit the biological responses Radiopharmaceuticals used to image the tumor receptor systems may be ligands for the specific receptors and antibodies for the growth factor receptors. Some antitumor agents have been labeled with radionuclides and used to study in vivo biodistribution and pharmacokinetics in humans. This overview describes typical PET radiopharmaceuticals used for tumor imaging based on their uptake mechanisms.

Keywords

References

  1. Shields AF, Graham MM, Spence AM. The role ofPET imaging in clinical oncology. A current statusreport. In: Freeman LM, editor. Nuclear MedicineAnnual. New York: Raven Press; 1995. p. 129-68.
  2. Stocklin GL. Is there a future for clinicalfluorine-I8 radiopharrnaceuticals (excluding PDG)?Eur J Nucl Med 1998;25:1612-6.
  3. Varagnolo L, Stokkel MPM, Mazzi U, PauwelsEKJ. ISP_Iabeled radiopharmaceuticals for PET inoncology, excluding PDG. Nucl Med Bioi 2000;27:103-12.
  4. Ido T, Wan CN, Casella V, Fowler IS, Wolf AP,Reivich M, et al. Labeled 2-deoxy-2-gluocseanalogs. ISF-Iabeled 2-deoxy-2-fluoro-D-glucose,2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoroD-glucose. J Labelled Cpd Radiopharm1978;14:178-83.
  5. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2_[ISp] fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic fluorination. Appl Radiat [sot 1986;37:235-8.
  6. Koh WJ, Rasey JS, Evans ML, Grierson JR,Lewellen TK, Graham MM, et al. Imaing ofhypoxia in human tumors withC8P]fluoromisonidazole. Int J Radiat Oneal BioiPhys 1992;22:199-212.
  7. Tewson TJ. Synthesis of C8F]fluoroetanidazole: apotential new tracer for imaging hypoxia. Nucl MedBioi 1997;24:755-60.
  8. Coenen HH, Kling P, Stocklin G. Cerebralmetabolism of L-[2-18F]fluorotyrosine, a new PETtracer of protein synthesis. J Nucl Med 1989;30:1367-72.
  9. Tomiyoshi K, Amed K, Muhammad S, Higuchi T,Inoue T, Endo K, et al. Synthesis of isomers of18P-Iabelled amino acid radiopharmaceutical:position 2- and 3-L-18P-alpha-methyltyrosine usinga separation and purification system. Nucl MedCornrnun 1997;18:169-75.
  10. Wester. HJ, Herz M, Weber W, Heiss P,Senekowitsch-Schmidtke R, Schwaiger M, et al.Synthesis and radiophanrncology of 0-(2-Cl}]flucroethyl)L-tyrosine for tumor imaging. J Nucl Med1999;40:205-12.
  11. Comar D, Cartron JC, Maziere M, Marazano C.Labelling and metabolism of methionine-methyl-I'C.Eur J Nucl Med 1976;1:11-4.
  12. Langstrom B, Lundqvist H. The preparation ofllC-methyl iodide and its use in the synthesis ofllC-methyl-L-methionine. Int J Appl Radiat [sot1976;27:357-63.
  13. Shoup TM, Olson J, Hoffman JM, Votaw J,Eshima D, Eshima L, et al. Synthesis andevaluation of C8F]l-amino-3-fluorocyclobutane-lcarboxylicacid to image brain tumors. J Nucl Med1999;40:331-8.
  14. Conti PS, Alauddin MM, Fissekis JR, Schmall B,Watanabe KA. Synthesis of 2'-fluoro-5-C1C]-methyll-bera-Dvarabinofuranosyluracil ([llC]-FMAU): apotential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Bioi1995;22:783-9.
  15. Grierson JR, Shields AP, Eary JF. Development ofradiosynthesis for 3' -[P-18]fluoro-3' -deoxynucleosides.J Labelled Cpd Radiopharrn 1997;40:60-2.
  16. Shields AP, Grierson JR, Dohmen BM, MachullaH-J, Stayanoff JC, Lawhorn-Crews JM, et al.Imaging proliferation in vivo with [P-18]PLT andposition emission tomography. Nat Med 1998;4:1334-6.
  17. Katzenellenbogen JA, Welch MJ, Dehdashti F. Thedevelopment of estrogen and progestinradiopharmaceuticals for imaging breast cancer.Anticancer Res 1997;17:1573~6.
  18. Kiesewetter DO, Kilbourn MR, Landvatter SW,Heiman DP, Katzenellenbogen JA, Welch MJ.Preparation of four fluorine-18-labeled estrogensand their selective uptakes in target tissues ofimmature rats. J Nucl Med 1984;25:1212-21.
  19. Lim JL, Zheng L, Berridge MS, Tewson TJ. Theuse of 3-methoxymethyl-16P,17p-epiestriol-O-cyclicsulfone as the precursor in the synthesis of P-18 16a-fluoroestradiol. Nucl Med Bioi 1996;23:911-5.
  20. Romer J, Steinbach J, Kasch H. Studies on thesynthesis of 16 a-C8P]fluoroestradiol. Appl Radiat[sot 1996;47:395-9.
  21. Hostetler ED, Jonson SD, Welch MJ,Katzenellenbogen JA. 2-[P-18]fluoroestradiol: areceptor-based radiopharmaceutical with highbinding for SHBG. J Nucl Med 1998;39S:35P.
  22. Pomper MG, Katzenellenbogen JA, Welch MJ,Brodack JW, Mathias CJ. 21-C8P]Fluoro-16a-ethyl-19-norprogesterone: synthesis and targettissue selective uptake of a progestin receptor basedradiotracer for Positron Emission Tomography. JMed Chern 1988;31:1360-3.
  23. Kochanny MJ, VanBrocklin HP, Kym PR, CarlsonKE, O'Neil JP, Bonasera TA, et al.Fluorine-18-labeled progestin ketals: synthesis andtarget tissue uptake selectivity of potential imagingagents for receptor-positive breast tumors. J MedChern 1993;36:1120-7.
  24. Buckman BO, Bonasera TA, Kirschbaum KS,Welch MJ, Katzenellenbogen JA. Fluorine-18labeledprogestin 16 a,17 a-dioxolanes: developmentof high-affinity ligands for the progesteronereceptor with high in vivo target site selectivity. JMed Chern 1995;38:328-37.
  25. Carlson KE, Katzenellenbogen JA. A comparativestudy of the selectivity and efficiency of targettissue uptake of five tritium-labeled androgens inthe rat. J Steroid Biochern 1990;36:549-61.
  26. Liu A, Carlson KE, Katzenellenbogen JA. Synthesisof high affinity fluorine-substituted ligands for theandrogen receptor. Potential agents for imagingprostatic cancer by positron emission tomography. JMed Chern 1992;35:2113-29.
  27. Choe YS, Lidstrom PJ, Chi DY, Bonasera TA,Welch MJ, Katzenellenbogen JA. Synthesis of 11 /3_[18Flfluoro-5 a-dihydrotestosterone and 11 /3- [18Fl fluoro-19-nor-5 a -dihydrotestosterone:preparation via halofluorination-reduction, receptorbinding and tissue distribution. J Med Chern1995;38:816-25.
  28. Bonasera TA, O'Neil JP, Xu M, Dobkin JA, CutlerPD, Lich LL, et al. Preclinical evaluation offluorine-18-labeled androgen receptor ligands inbaboons. J Nucl Med 1996;37:1009-15.
  29. Eigtved A, Jensen M, Holm S, Foder B, Larsen P,Hoejgaard L, et al. [F-18lFluoro-5 a-dihydrotestosterone as a PET ligand for androgenreceptors in prostate cancer. J Nucl Med1999;40S:256P.
  30. Shiue CY, Bai LQ, Shiue GG, Rysavy JA, PleusRC, Hui H, et al. Synthesis of (+/-)-C8FlBMY14802, its enantiomers and their anatomical distributionsin rodents. Nucl Med Bioi 1993;20:625-30.
  31. Collier TL, O'Brien JC, Waterhouse RN. Synthesisof [18F] 1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: a potential sigma-I receptor radioligandfor PET. J Labelled Cpd Radiopharrn 1996;38:78594
  32. Kawamura K, Ishiwata K, Tajima H, Ishii S-I, Matsuno K, Homma Y, et al. In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS Sigma1 receptors. Nucl Med Bioi 2000;27:255-61.
  33. Wester H-J, Hamacher K, Stocklin G. Acomparative study of N.C.A. fluorine-18 labelingodf proteins via acylation and photochemicalconjugation. Nucl Med Bioi 1996;23:365-72.
  34. Guhlke S, Wester HJ, Bruns C, Stocklin G.(2C8F]Fluoropropionyl-(D)phel)-octreotide, a potentialradiopharmaceutical for quantitative somatostatinreceptor imaging with PET: synthesis, radiolabeling,in vitro validation and biodistribution in mice. NuclMed Bioi 1994;21:819-25.
  35. Dimitrakopoulou A, Strass LG, Clorius JH,Ostertag H, Schlag P, Heim M, et al. Studies withPET after systematic administration of fluorine-18uracilin patients with liver metastases fromcolorectal carcinoma. J Nucl Med 1993;34:1075-81.
  36. Oberdorfer F, Hofmann E, Maier-Brost W.Preparation of 18F-labeled 5-fluorouracil of veryhigh purity. J Labelled Cpd Radiopharm 1989;30:543-9.
  37. Tyler JL, Yamamoto YL, Diksic M, Theron J,Villemure JG, Worthington C, et aLPharmacokinetics of superselective intra-arterial andintravenous [11C]BCNU evaluated by PET. J NuclMed 1986;27:775-80.
  38. Ginos JZ, Cooper AJL, Dhawan V, Lai JCK,Strother SC, Alcock N, et al. C3N1Cisplatin PET toassess pharmacokinetics of intra-arterial versusintravenous chemotherapy for malignant braintumors. J Nucl Med 1987;28:1844-52.
  39. Kiesewetter DO, Eckelman WC. Radiochemicalsynthesis of C8Flfluoropaclitaxel (C8FlFPAC). JLabelled Cpd Radiopharrn 2001;44:S903-5.
  40. Kurdziel KA, Kiesewetter DO, Carson RE,Eckelman WC, Herscovitch P. Biodistribution,radiation dose estimates and PGP modulationstudies of 18Fpaclitaxel. J Nucl Med 2001;42S:279P.
  41. Yang D, Kuang LR, Cherif A, Tansey W, Li C,Lin WJ, et al. Synthesis of C8Flfluoroalanine and[18Flfluorotamoxifen for imaging breast tumors. J Drug Target 1993;1:259-67.
  42. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC,Bassa P, et al. Positron emission tomography usingeSF]fluorotamoxifen to evaluate therapeutic responsesin patients with breast cancer: preliminary study.Cancer Biotherapy Radiopharm 1996;11:235-45.
  43. Park BN, Choe YS, Chi DY, Choi Y, Lee KH,Kim SE, et al. Synthesis of 2-[methyl-11qmethoxyestradiol for in vivo studies of tumorangiogenesis. J Labelled Cpd Radiopharm 1999;42:S432-3.
  44. Brady F, Luthra SK, Brown G, Osman S, HarteRJA, Denny WA, et al. Carbon-l l labelling of theantitumor agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and determination ofplasma metabolites in man. Appl. Radiat. Isot.1997;48:487-92.
  45. Barrio JR, Namavari M, Srinivasan A, Gambit S,Cherry S, Herschman H, et al. Carbon-8radiofluorination of purines; a general approach toprobe design for gene therapy in humans. JLabelled Cpd Radiopharm 1997;40:S348.
  46. Alauddin MM, Conti PS, Mazza SM, Harnzeh PM,Lever JR. 9-[(3-esF]-Fluoro-l-hydroxy-2-propoxy)methyl]guanine ([lsF]_FHPG): a potential imagingagent of viral infection and gene therapy usingPET. Nucl Med Bioi 1996;23:787-92.